

14 July 2023

ASX Code: MXC

LSE Code: MXC

Notice Under Section 708A(5) of the Corporations Act 2001 (the Act)

This notice is given by MGC Pharmaceuticals Limited (ASX: MXC) (“**MGC Pharma**” or the “**Company**”) in relation to the issue of 541,666,667 fully paid ordinary shares (Shares) as detailed in the Appendix 2A announced today.

The Corporations Act 2001 (Cth) (Act) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares detailed in the Appendix 2A announced on 14 July 2023 will fall within the exemption in section 708A(5) of the Act. Pursuant to section 708A(5)(e) of the Act, the Company gives notice that:

- a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- b) as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and sections 674 and 674A of the Act; and
- c) as at the date of this notice there is no information:
 - i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
 - ii) that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
 - 1) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - 2) the rights and liabilities attaching to the Shares.

—Ends—

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@mgcpharma.co.uk

UK Brokers
Peterhouse Capital
Charles Goodfellow / Lucy Williams / Duncan Vasey
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd
Arron Canicais / Rowan Harland
Joint Company Secretaries
+61 8 6555 2950
info@mgcpharma.co.uk

UK Brokers
Oberon Capital
Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma